Robert Gordon

Home Care Policy Analyst · LinkedIn · May 8, 2026

14 min read

At-Home Leqembi Injections Are Here: What Orange County Dementia Families Need to Know

For years, treating early Alzheimer’s disease with lecanemab (Leqembi) meant biweekly trips to an infusion center — IV drips lasting over an hour, careful post-infusion observation, and a significant logistical burden for families already stretched thin by caregiving. Transportation arrangements, missed workdays, and the sheer fatigue of clinic routines added to the emotional weight of an Alzheimer’s diagnosis.

That changed in August 2025, when the FDA approved Leqembi Iqlik — a subcutaneous autoinjector that delivers the same lecanemab medication in approximately 15 seconds, right at home. If your loved one has been on intravenous Leqembi for 18 months or more, the transition to weekly home injection may already be available to them.

An even bigger milestone is on the horizon: the FDA is currently reviewing a supplemental application that could allow patients to start Leqembi treatment with subcutaneous injections — with no IV phase required at all. The FDA’s PDUFA action date for that decision is August 24, 2026.

For Orange County families navigating Alzheimer’s care in Irvine, Anaheim, Fullerton, Santa Ana, Newport Beach, or anywhere across OC, these developments could fundamentally reshape what daily treatment looks like — and what non-medical home care support looks like alongside it.

What Is Leqembi Iqlik?

Lecanemab — sold under the brand name Leqembi — is a monoclonal antibody that targets amyloid beta plaques, the protein clusters in the brain closely associated with Alzheimer’s disease progression. The FDA granted full approval to IV Leqembi in July 2023, making it the first Alzheimer’s drug to receive traditional approval based on demonstrated slowing of cognitive decline — not just symptom management.

Leqembi Iqlik (pronounced “I Click”) is the subcutaneous formulation. It contains 360 mg of lecanemab in 1.8 mL, delivered via a prefilled autoinjector pen — similar in concept to devices used for insulin or GLP-1 medications. The medication is injected just under the skin (subcutaneously), typically in the abdomen, thigh, or upper arm.

The FDA approved Leqembi Iqlik for maintenance dosing on August 29, 2025, and it became commercially available in the United States on October 6, 2025. It is currently indicated only for patients who have already completed the initial IV initiation phase — 18 months of biweekly IV infusions — and who are confirmed candidates for continued lecanemab treatment.

From Infusion Center to Living Room: What Changed

The practical shift for families is significant. Under the original IV protocol, patients needed to:

• Schedule an appointment at an infusion center every two weeks
• Arrange reliable transportation (infusions take 60–90 minutes, plus observation time)
• Plan their week around clinic days — including coordination with work schedules
• Monitor for infusion reactions in a clinical setting

With Leqembi Iqlik, the weekly injection takes roughly 15 seconds. It can be self-administered by the patient — or administered by a trained family caregiver — in the comfort of home. The schedule shifts from biweekly clinic visits to once-weekly home dosing that fits naturally into an existing caregiving routine.

For OC families, this matters practically. Whether your loved one is in Huntington Beach, Mission Viejo, Costa Mesa, or Tustin, eliminating biweekly infusion trips can reduce disruptions to daily rhythms that Alzheimer’s research shows are crucial to cognitive stability. It also reduces the physical fatigue that often accompanies repeated clinic travel for older adults with early-stage disease.

Comparison: IV Infusion vs. Home Subcutaneous Injection

Who Qualifies for Home Injection Today?

Currently, Leqembi Iqlik is available to patients who meet all of the following criteria:

• Early-stage Alzheimer’s — mild cognitive impairment (MCI) or mild dementia stage
• Biomarker-confirmed amyloid pathology — confirmed via amyloid PET scan or cerebrospinal fluid (CSF) analysis
• Completion of 18-month IV phase — biweekly IV lecanemab infusions successfully completed
• No severe ARIA events — no serious amyloid-related imaging abnormalities during treatment that would contraindicate continuation
• Clinical confirmation — prescribing neurologist has determined the patient is a maintenance-phase candidate

If your loved one is currently in the IV initiation phase, they may already be building toward eligibility for home injection in the future. Talk with their neurologist about whether the transition to Iqlik is on the treatment roadmap.

ARIA: What Every OC Caregiver Needs to Know

ARIA stands for Amyloid-Related Imaging Abnormalities — a potential side effect associated with lecanemab treatment. ARIA most commonly appears as temporary swelling in brain tissue (ARIA-E, edema) or as small spots of superficial bleeding (ARIA-H, hemosiderin deposits). The majority of ARIA cases are mild and produce no symptoms — they’re detected on routine MRI scans during the IV initiation phase.

The important news for home injection patients: during the maintenance phase with Leqembi Iqlik, routine MRI monitoring is no longer required. Unlike the IV phase — where regular brain imaging is part of the standard protocol — the subcutaneous maintenance phase relies on symptom-based monitoring. If a patient develops new or concerning symptoms, a clinical evaluation (and MRI if indicated) should be done promptly.

This is where daily at-home observation becomes critically important. Family caregivers and in-home aides are often the first to notice subtle changes that may indicate ARIA:

Most people on Leqembi maintenance dosing tolerate it well. But keeping a brief daily symptom log — noting any changes in behavior, speech, balance, or cognition — provides both peace of mind and a concrete record for the neurologist at quarterly check-ins.

How Non-Medical Home Care Supports Leqembi Families

AHVA’s trained in-home aides are not licensed nurses and cannot administer prescription injectable medications. But non-medical home care plays a vital — and often underappreciated — support role for families managing Alzheimer’s treatment at home. Here’s where we fit:

Daily Symptom Observation

A trained home aide who knows the patient’s baseline can notice subtle shifts — new confusion, a change in gait, unusual fatigue — that may warrant a call to the neurologist. Consistent, observant presence is one of the most valuable things non-medical care provides in a medical-adjacent treatment environment.

Medication Schedule and Routine Support

Aides can provide gentle weekly injection reminders, document when doses occur, and maintain the kind of predictable daily routine — meals, activities, sleep — that stabilizes cognition in Alzheimer’s patients. They cannot administer the medication, but supporting the context around treatment is genuinely therapeutic.

Caregiver Respite

When a family member is also the injection administrator, the emotional weight of that responsibility can compound caregiving fatigue. AHVA aides provide regular respite hours so that family caregivers can rest, manage their own health, and return to the caregiving role refreshed.

Transportation and Logistics

Even on home injection, quarterly neurologist check-ins, specialty pharmacy pickups, and unexpected clinic visits remain part of the routine. AHVA provides transportation coordination and accompaniment throughout Orange County.

What the August 2026 FDA Decision Could Mean for OC Families

Currently, the pathway to Leqembi Iqlik requires 18 months of biweekly IV infusions first. That’s a significant commitment — in time, logistics, and cost — that not every family can sustain. For patients in rural areas, those without reliable transportation, or those whose health makes repeated clinic travel difficult, the IV phase creates a real access barrier.

The pending FDA application would change this fundamentally. If approved on August 24, 2026, patients newly diagnosed with early Alzheimer’s could begin lecanemab treatment directly via weekly subcutaneous injection — no IV phase, no infusion center required from day one. This would make the treatment accessible to many OC families who currently cannot navigate an 18-month clinic schedule.

Eisai and Biogen’s FDA submission was accepted under Priority Review — the FDA’s designation for treatments that may offer significant improvements over existing options. While priority review doesn’t guarantee approval, it signals the agency recognizes the potential impact. The FDA noted it has not raised concerns about the approvability of the application, though it requested additional data that extended the review window by three months.